Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index; 17 of the 41 sources its claims cite were checked for support.

A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality

Open access

Abstract

Objective: To assess the efficacy and safety of Vortioxetine and Escitalopram in improving cognition in patients with major depressive disorder (MDD). Methods: At baseline, 131 MDD patients and 70 healthy controls completed the Hamilton Depression Scale (HAMD-17), Hamilton Anxiety Scale (HAMA), Snaith-Hamilton Pleasure Scale (SHAPS) and MATRICS Consensus Cognitive Battery (MCCB). Patients with MDD were randomly divided into Vortioxetine (n = 62) and Escitalopram (n = 69) groups with an 8-week follow-up research. ANOVA for repeated measurement was utilized to compare the efficacy of Vortioxetine and Escitalopram. Results: The total scores of HAMD-17, HAMA and SHAPS scales had statistical difference between MDD cases and healthy controls (P < 0.001) at baseline. After 8 weeks of treatment, the scale scores of the HAMD-17, HAMA and SHAPS had lowered in both groups, with no statistical difference between two groups (P > 0.05). At baseline, MDD patients had defects in Speed of Processing, Attention Vigilance, Verbal Learning, Visual Learning, Reasoning and Problem Solving, and Social Cognition, compared with healthy controls. After 8 weeks of treatment with Vortioxetine or Escitalopram, the patients had improved in the aspects of cognitive functions above except Social Cognition. Numerical improvements of MCCB scale were found in the two groups, P > 0.05. Most adverse events were mild or moderate, with nausea being the most common adverse event. Conclusion: Both Vortioxetine and Escitalopram can improve the mental status and cognitive functions in MDD patients, with mild or moderate adverse events. Trial Registration: www.chictr.org.cn, identifier: ChiCTR1900024858.

Overview

CoChat Summary

TL;DR

In this 8-week randomized active-controlled trial in Chinese Han patients with MDD, vortioxetine and escitalopram both improved depressive/anxiety/pleasure symptoms and several cognitive domains, with no statistically significant between-drug differences. Adverse events were mostly mild or moderate, with nausea most common.

Key findings

  • At baseline, MDD patients differed from healthy controls on HAMD-17, HAMA, and SHAPS total scores (P < 0.001) and on MCCB domains including Speed of Processing, Attention Vigilance, Working Memory, Verbal Learning, Visual Learning, Reasoning and Problem Solving, and Social Cognition (all P < 0.05).
  • After 8 weeks, HAMD-17 (F = 209.638, P < 0.001), HAMA (F = 122.323, P < 0.001), and SHAPS (F = 13.907, P < 0.001) scores decreased over time in both groups, with no between-group difference at baseline, 2, 4, or 8 weeks (all P > 0.05) and no drug-by-time interaction (P > 0.05).
  • Cognitive improvements: vortioxetine improved Attention Vigilance (45.15 vs 50.31), Speed of Processing (39.73 vs 47.65), Working Memory (39.78 vs 45.22), Verbal Learning (40.26 vs 47.19), and Reasoning and Problem Solving (41.70 vs 48.67) (P1 < 0.05); escitalopram improved Speed of Processing (41.63 vs 48.77), Attention Vigilance (44.39 vs 47.84), Verbal Learning (43.23 vs 50.00), Visual Learning (43.42 vs 49.63), and Reasoning and Problem Solving (43.56 vs 49.07) (P2 < 0.05). No between-group MCCB differences were found after 8 weeks (all P3 > 0.05).
  • Safety: 58 TEAEs occurred, 33 (53.2%) with vortioxetine and 25 (36.2%) with escitalopram; nausea was most common, in 22 (35.5%) vortioxetine and 13 (18.8%) escitalopram patients. Most adverse events were mild or moderate; no deaths or serious adverse events occurred.

Methods

  • Randomized, active-controlled, 8-week head-to-head study at the First Affiliated Hospital, College of Medicine, Zhejiang. A total of 131 MDD patients were randomized to vortioxetine (n = 62) or escitalopram (n = 69); 70 healthy controls were matched by age, sex, and years of education. Inclusion required age 18–45, DSM-5 MDD, HAMD-17 ≥ 17, Han nationality, right-handedness, and junior high school education or above.
  • Assessments included HAMD-17 as primary efficacy measure, HAMA and SHAPS as secondary efficacy measures, MCCB for cognition at baseline and week 8, and TEAEs for safety. Randomization used a computer-generated scheme stratified by center; efficacy/safety assessors were blind to treatment.
  • Analyses used ITT (all randomized patients receiving ≥1 dose and ≥1 postbaseline HAMD-17 assessment) and PP sets; repeated-measures mixed-effect models/ANOVA compared groups over time, with LOCF for HAMD-17 and SPSS 21.0.

Limitations

  • The paper states a relatively high attrition rate and small sample size, possibly worsened by COVID-19 restrictions, limited access to vortioxetine in smaller cities, and higher vortioxetine price; it also notes possible low sensitivity of HAMD-17, HAMA, SHAPS, and MCCB, a short 8-week treatment period, and no inclusion of biomarkers such as plasma factors, intestinal flora, or MRI.
  • Evident from the text: dropout was differential by group (31/62 vortioxetine vs 47/69 escitalopram completed 8 weeks), and cognitive comparisons used the smaller PP set (31 vs 47), which may reduce power and bias between-group cognitive conclusions.
  • Evident from the text: despite randomization, baseline Working Memory MCCB scores differed significantly between the vortioxetine and escitalopram groups (P < 0.01).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2147/ndt.s491768

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 CONSORT diagram of participants through the trial.
Figure 1 CONSORT diagram of participants through the trial.CC BY-NC · PubMed Central
Figure 2 HAMD-17 scores were significantly improved after the 8 weeks use of Escitalopram and Vortioxetine. ####P < 0.0001 in Vortioxetine group. ****P < 0.0001 in Escitalopram group. n.s.P > 0.05.
Figure 2 HAMD-17 scores were significantly improved after the 8 weeks use of Escitalopram and Vortioxetine. ####P < 0.0001 in Vortioxetine group. ****P < 0.0001 in Escitalopram group. n.s.P > 0.05.CC BY-NC · PubMed Central

Verification

Claims the paper makes

12 Valid · 1 Not valid · 17 Not checked · 37 Own results and interpretations

24 more claims

Create a free account to see all 67 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 23
  • It may state two separate claims as one. 20
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 58 references

Cited by

See all 3

Metadata

Authors
Ye, X., Xu, P., Jiao, J., Zhao, H., Jin, K., Zhang, S., Pan, F., Chen, J., Jiang, H., Hu, J., & Huang, M.
Affiliations
First Affiliated Hospital Zhejiang University (CN)
Corresponding author
Huang, Manli
Venue
Neuropsychiatric Disease and Treatment
Published
2024-12
Volume
Volume 20
Pages
2363-2374
ISSN
  • 1176-6328 (ISSN-L)
  • 1178-2021
OpenAlex
W4405083566
Cited by
3
References
58
Citations by year
2026: 2 · 2025: 1
FWCI
0.85
Type
journal article
Language
en
Open access
Locations
  • Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
National Natural Science Foundation of China (2023C03077, 82271562)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
vortioxetine, escitalopram, major depressive disorder, cognitive function, antidepressant efficacy, adverse events, social cognition, Chinese Han patients, MATRICS Consensus Cognitive Battery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality. https://app.cochat.ai/papers/10.2147/ndt.s491768
The paper
Ye, X., Xu, P., Jiao, J., Zhao, H., Jin, K., Zhang, S., Pan, F., Chen, J., Jiang, H., Hu, J., & Huang, M. (2024). A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s491768

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.